Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to $106.7 million.

  • aTYR PHARMA's Liabilities and Shareholders Equity rose 1641.2% to $106.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $402.3 million, marking a year-over-year decrease of 676.73%. This contributed to the annual value of $96.8 million for FY2024, which is 1974.51% down from last year.
  • Latest data reveals that aTYR PHARMA reported Liabilities and Shareholders Equity of $106.7 million as of Q3 2025, which was up 1641.2% from $101.5 million recorded in Q2 2025.
  • aTYR PHARMA's Liabilities and Shareholders Equity's 5-year high stood at $136.8 million during Q1 2023, with a 5-year trough of $49.0 million in Q2 2021.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $104.8 million (2022), whereas its average is $103.4 million.
  • As far as peak fluctuations go, aTYR PHARMA's Liabilities and Shareholders Equity skyrocketed by 19834.48% in 2021, and later crashed by 2674.76% in 2024.
  • Quarter analysis of 5 years shows aTYR PHARMA's Liabilities and Shareholders Equity stood at $115.5 million in 2021, then dropped by 17.09% to $95.8 million in 2022, then rose by 25.96% to $120.7 million in 2023, then fell by 19.75% to $96.8 million in 2024, then rose by 10.14% to $106.7 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $106.7 million for Q3 2025, versus $101.5 million for Q2 2025 and $97.2 million for Q1 2025.